2024年至2032年人类微生物组市场机会、成长动力、产业趋势分析与预测

2023 年，全球人类微生物组市场价值为 8.424 亿美元，预计将经历显着增长，2024 年至 2032 年的年复合成长率(CAGR) 为25.7%。不断提高在健康和疾病管理中发挥重要作用。随着製药业越来越多地采用基于微生物组的疗法，市场有望大幅扩张。对个人化医疗的需求以及与微生物组靶向干预相关的治疗可能性是推动这一增长的重要因素。对微生物组如何影响人类健康的更深入了解推动了该领域的研究和开发，特别是针对慢性疾病和代谢紊乱患病率上升的情况。

人类微生物组市场依不同的解剖部位进行分类，包括消化道、肺部、生殖腔、皮肤和其他部位。其中，消化道部分所占份额最大，到 2023 年将达到 31.7%。研究越来越关注肠道微生物群失衡的影响，肠道微生物群失衡与各种健康问题有关，包括肥胖和发炎性肠道疾病 (IBD)。市场也按治疗和诊断应用进行细分。

治疗领域在2023 年占据64.7% 的市场份额，预计到2032 年将实现快速增长。疗法。该公司正在积极开发基于微生物组的治疗方法，重点关注胃肠道疾病、代谢疾病和免疫相关疾病，其中许多治疗方法正在临床试验中。

北美在人类微生物组市场中处于领先地位，到2023 年价值将达到2.612 亿美元，预计到2032 年复合年增长率为24.9%。以及对微生物组治疗的投资不断增加。随着更多基于微生物组的疗法获得监管部门的批准，该地区对创新的强有力的监管支持、不断增长的医疗保健支出以及对个性化医疗意识的提高使其能够实现持续的市场增长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 与生活方式相关的疾病负担日益加重，老年人口不断增加
    • 增加资助计划和政府计划
    • 精准医疗需求不断成长
    • 监理途径长、开发成本高
  • 产业陷阱与挑战
    • 道德和安全问题
• 成长潜力分析
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：人类微生物组市场：依地点划分，2018 年 - 2032 年

• 主要趋势
• 消化道
• 肺
• 生殖腔
• 皮肤
• 其他网站

第 6 章：人类微生物组市场：依应用分类，2018 - 2032

• 主要趋势
• 疗法
• 诊断

第 7 章：人类微生物组市场：依疾病分类，2018 - 2032

• 主要趋势
• 传染病
• 胃肠道疾病
• 内分泌及代谢疾病
• 癌症
• 中枢神经系统失调
• 其他疾病

第 8 章：人类微生物组市场：依产品分类，2018 - 2032

• 主要趋势
• 药品
• 益生菌
• 益生元
• 诊断测试
• 其他产品

第 9 章：人类微生物组市场：按地区划分，2018 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
• 拉丁美洲
  • 巴西
  • 墨西哥
• MEA
  • 南非
  • 沙乌地阿拉伯

第 10 章：公司简介

• Seres Therapeutics
• Enterome
• Second Genome Inc.
• DuPont
• Synthetic Biologics, Inc.
• Synlogic
• Vedanta Biosciences, Inc.
• Metabiomics Corporation
• MICROBIOME THERAPEUTICS LLC
• 4D pharma plc

The Global Human Microbiome Market was valued at USD 842.4 million in 2023 and is projected to experience remarkable growth, with a compound annual growth rate (CAGR) of 25.7% from 2024 to 2032. This surge is largely fueled by the growing recognition of the microbiota's essential role in health and disease management. As the pharmaceutical sector increasingly adopts microbiome-based therapies, the market is poised for substantial expansion. The demand for personalized medicine and the therapeutic possibilities associated with microbiome-targeted interventions are significant factors driving this growth. A deeper understanding of how the microbiome influences human health propels research and development in this field, particularly in response to the rising prevalence of chronic illnesses and metabolic disorders.

The human microbiome market is categorized by various anatomical sites, including the digestive tract, lungs, reproductive cavity, skin, and other locations. Among these, the digestive tract segment held the largest share at 31.7% in 2023. The gut microbiome is crucial for digestion, immune function, and overall well-being, making it a primary focus for microbiome-based therapies. Research is increasingly focused on the effects of imbalances in gut microbiota, which are linked to various health issues, including obesity and inflammatory bowel disease (IBD). The market is also segmented by application into therapeutics and diagnostics.

The therapeutics sector accounted for 64.7% of the market share in 2023 and is anticipated to see rapid growth through 2032. As researchers gain insights into the microbiome's role in numerous diseases, there is a concerted effort to develop therapies that can modulate or restore healthy microbiota. Companies are actively developing microbiome-based treatments focusing on gastrointestinal disorders, metabolic diseases, and immune-related conditions, with many in the pipeline for clinical trials.

North America leads the human microbiome market, achieving a value of USD 261.2 million in 2023, with a projected CAGR of 24.9% through 2032. This dominance can be attributed to major pharmaceutical firms, a robust research infrastructure, and increasing investments in microbiome therapeutics. The region's strong regulatory support for innovation, rising healthcare expenditures, and heightened awareness of personalized medicine positions it for sustained market growth as more microbiome-based therapies gain regulatory approval.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing burden of lifestyle-related diseases and the growing geriatric population
    • 3.2.1.2 Increasing funding initiatives and government program
    • 3.2.1.3 Increasing demand precision medicine
    • 3.2.1.4 Long regulatory pathways and high development costs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Ethical and safety concern
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Human Microbiome Market, By Site, 2018 - 2032 (USD Million)

• 5.1 Key trends
• 5.2 Digestive tract
• 5.3 Lung
• 5.4 Reproductive cavity
• 5.5 Skin
• 5.6 Other sites

Chapter 6 Human Microbiome Market, By Application, 2018 - 2032 (USD Million)

• 6.1 Key trends
• 6.2 Therapeutics
• 6.3 Diagnostics

Chapter 7 Human Microbiome Market, By Disease, 2018 - 2032 (USD Million)

• 7.1 Key trends
• 7.2 Infectious diseases
• 7.3 Gastrointestinal diseases
• 7.4 Endocrine & metabolic diseases
• 7.5 Cancer
• 7.6 Central nervous system disorder
• 7.7 Other diseases

Chapter 8 Human Microbiome Market, By Product, 2018 - 2032 (USD Million)

• 8.1 Key trends
• 8.2 Drugs
• 8.3 Probiotics
• 8.4 Prebiotics
• 8.5 Diagnostic tests
• 8.6 Other products

Chapter 9 Human Microbiome Market, By Region, 2018 - 2032 (USD Million)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia

Chapter 10 Company Profiles

• 10.1 Seres Therapeutics
• 10.2 Enterome
• 10.3 Second Genome Inc.
• 10.4 DuPont
• 10.5 Synthetic Biologics, Inc.
• 10.6 Synlogic
• 10.7 Vedanta Biosciences, Inc.
• 10.8 Metabiomics Corporation
• 10.9 MICROBIOME THERAPEUTICS LLC
• 10.10 4D pharma plc